List view / Grid view
The researchers argue hepatocytes are susceptible to SARS-CoV-2 pseudovirus infection and propose that metformin could be a therapeutic option to attenuate SARS-CoV-2 infection in patients with fatty liver.
As COVID-19 continues to evolve, researchers are still on the lookout for new ways to protect against the virus. Drug Target Review brings you some of the most recent pre-clinical developments.
Using a natural language-inspired technique, researchers at the University of Central Florida, US, developed an interpretable and generalisable drug target interaction model that achieves 97 percent accuracy in identifying drug candidates for a broad variety of target proteins. Here, Dr Ozlem Ozmen Garibay and Aida Tayebi, who worked on the…
Opioid addiction is an ongoing crisis in the US. Researchers have identified a key regulator that shapes analgesic and aversive outputs of kappa opioid receptor signalling, finding lead inhibitors of this previously ‘undruggable’ target class – the Regulators of G protein Signalling (RGS proteins) – to help re-establish non-addictive kappa…
US researchers have tested mRNA-based vaccine against influenza viruses, with promising results in animal models, that pave the way for clinical trials.
US researchers showed that the protein: GRP78, implicated in COVID-19 and cancers, is effected by the new drug HA15.
US researchers have utilised a cancer immunotherapy technique, CAR-T cell method to effectively eliminate SARS-CoV-2 virus pre- and post-infection in vitro.
SK bioscience and IVI convened in consultative meeting to discuss cooperation for next pandemic and announced KRW3 billion donation to IVI to support advancement of global vaccine R&D
South Korean researchers identified two saponins there were highly effective in blocking the ability of SARS-CoV-2 variants to enter cells.
Australian researchers have tested a new nasal vaccine in mice, with the potential enhance protection against COVID-19.
In their study, the researchers from the University of Maryland School of Medicine found that the Nsp6 SARS-CoV-2 protein causes heart damage.
Pre-clinical experiments involving cells from ICUs patients infected by SARS-CoV-2, and mice infected by MHV-A59 (murine hepatitis virus A59) show promise in treating COVID-19.
Anti-inflammatory effects of niclosamide, observed in a new pre-clinical study, were due to inhibition of the inflammasome, a protein complex presented in the interior of defence cells.
H84T-BanLec has viral-blocking abilities by binding to polysaccharides that are present on the surface of the viruses.
A study has shown that mRNA delivered via lipid nanoparticles blocks multiple variants of SARS-CoV-2 from entering cells in mice.
